Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and value of health results.
The abstract entitled ‘Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial‘ Abstract 54MO, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What did the ABC-06 study teach us about the efficacy and safety of second-line active- symptom-control (ASC) with oxaliplatin/5-FU chemotherapy (FOLFOX) in the treatment of advanced biliary cancers (ABC)? (0:31)
- What was the rationale for this analysis of the ABC-06 data? (1:25)
- What were the findings of the analysis? (2:50)
- What questions remain unanswered and what further research is planned? (3:09)
Disclosures: Angela Lamarca has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
